All In Biotech

Drugs by condition

Drugs approved for alzheimer's disease

Brand-name prescription drugs and biologics whose FDA label lists alzheimer's disease as an approved use. Matched on the label phrases: "Alzheimer".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

0

Still marketed, NDA or BLA

Drug classes

0

Novel drugs

0

New molecular entities and new biologics

In development

40+

Investigational drugs in Phase 2 or 3

All approved drugs for alzheimer's disease, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 0 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

No current brand-name label names this in its indications. Try another name for the condition, or a broader term.

Drugs in development for alzheimer's disease

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials

    Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder

  • ObicetrapibPhase 37 trials

    NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption

  • ITI-1284JNJ-99245354Phase 36 trials

    Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders

  • NPI-001N-Acetylcysteine AmidePhase 35 trials

    Nacuity Pharmaceuticals, Inc. · Retinitis Pigmentosa (RP), Usher Syndrome, Alzheimer´s Disease

  • ACP-204Phase 34 trials

    ACADIA Pharmaceuticals Inc. · Alzheimer's Disease Psychosis, Lewy Body Dementia Psychosis

  • TrontinemabRO7126209, RG6102Phase 34 trials

    Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease

  • AXS-05dextromethorphan-bupropionPhase 33 trials

    Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation

  • buntanetapposiphenPhase 33 trials

    Annovis Bio Inc. · Early Alzheimers Disease, Alzheimer's Dementia (AD), Parkinson's Disease (PD)

  • MasitinibAB1010Phase 33 trials

    AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease

  • SPG302TazbentetolPhase 33 trials

    Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis

  • TertomotideGV1001Phase 33 trials

    GemVax & Kael · Moderate to Severe Alzheimer's Disease, Mild to Moderate Alzheimer's Disease, Progressive Supranuclear Palsy

  • [18F]-APN-1607Phase 32 trials

    JYAMS PET Research & Development Limited · Alzheimer's Disease, Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia

  • ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease

  • DMB-IINN: Latrepirdine, DimebonPhase 32 trials

    Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type

  • SemagludtidePhase 32 trials

    Lumos Pharma · Obesity & Overweight, Early Alzheimer's Disease

  • AR1001Phase 31 trial

    AriBio Co., Ltd. · Alzheimer Disease

  • EXV-801deramciclanePhase 31 trial

    Exciva GmbH · Agitation Associated With Alzheimer's Disease Dementia

  • EXV-802Phase 31 trial

    Exciva GmbH · Agitation Associated With Alzheimer's Disease Dementia

  • Wanbangde Pharmaceutical Group Co., LTD · Alzheimer Dementia

  • MLC 901Phase 31 trial

    Moleac Pte Ltd. · Alzheimer's Disease Dementia

More on alzheimer's disease: recruiting trials · published research

Related in neurology: Parkinson's disease · Multiple sclerosis · Epilepsy and seizures · Migraine · ALS (amyotrophic lateral sclerosis) · Myasthenia gravis · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.